 Home > Medical News > Medical Research Articles > Yimin Angko Next Generation Immune Checkpoint Inhibitors Approved for Treatment of Blood Cancers in NMPA Clinical Trials

Yimin Angko Next Generation Immune Checkpoint Inhibitors Approved for Treatment of Blood Cancers in NMPA Clinical Trials

 Last Update: 2020-06-09
 Source: Internet
 Author: User

Tags

drug classification list

cbd drug interactions

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

recently,, Yimin Angko Bio
Pharmaceutical(http://Technology (Shanghai) LimitedCompany
(http://("Yimin Angko"), announced that the company's new generation of immunocheckpoint inhibitors (item number: IMM01) has been granted the clinicaltesting(http://license of the NationalMedicines(http://Regulatory Authority (NMPA) (http:// for the treatment of cancer(The IMM01 project for injection is based on a new generation of immuno-checkpoint inhibitors with independent intellectual property rights developed on the yimin Angko "mAb-Trap" technology platform, and plays a powerful tumor immunotherapy effect by activating the phagocytophated phagocytosis of macrophages to the phagocytosis of tumor cellspreclinical research data confirm edi-IMM01 has achieved remarkable therapeutic results in a variety of tumor models, and because IMM01 does not bind to human red blood cells, it has obvious advantages in safetyIt is reported that YiMingAngko submitted IND to the State Drug Administration (NMPA) on March 18, 2019, and on May 14, 2019, approved the clinical I/II trial research license, which took only 39 working days from acceptance to approvalYiminenko submits the IND to theFDA(http://the approval of this project marks the entry of the first CD47 fusion proteindrug(http://research in China authorized by Yimin Angke to obtainPatent(http://independent research and development

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.